Emilimogene sigulactibac

N/A

Report date: 2025/02/06 16:57:10

Base Information

Drug NameEmilimogene sigulactibac

Drug Alias NameILP100hILP-100

ClassificationCell and gene therapy > Gene therapy > PlasmidCell and gene therapy > Gene therapy > Bacterial vector-based gene therapy > Limosilactobacillus reuteri bacteria vector

Mechanisms of ActionC-X-C motif chemokine ligand 12 stimulants

TargetsC-X-C motif chemokine ligand 12

Therapy Area/IndicationsWounds and InjuriesDiabetic Foot

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySweden

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesIlya Pharma AB

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesIlya Pharma AB

Active IndicationsN/A

Inactive IndicationsWounds and InjuriesDiabetic Foot

Other Information

ATC CodeN/A